Table 1 Summary of the clinical and pathologic information for the whole datasets and treatment information for the cohorts involved.
Adenocarcinoma (ad) (n = 1189) | Squamous cell carcinoma (scc) (n = 585) | All (n = 1774) | |
|---|---|---|---|
Dataset | |||
D1 (Yale) | 44 (3.7%) | 27 (4.6%) | 71 (4.0%) |
D2 (Yale) | 43 (3.6%) | 28 (4.8%) | 71 (4.0%) |
D3 (Yale) | 58 (4.9%) | 21 (3.6%) | 79 (4.5%) |
D4 (CCF) | 145 (12.2%) | 86 (14.7%) | 231 (13.0%) |
D5 (TCGA) | 427 (35.9%) | 423 (72.3%) | 850 (47.9%) |
D6 (UPenn) | 21 (1.8%) | 0 (0%) | 21 (1.2%) |
D7 (UBern) | 93 (7.8%) | 0 (0%) | 93 (5.2%) |
D8 (BMS) | 358 (30.1%) | 0 (0%) | 358 (20.2%) |
Sex | |||
Female | 518 (43.7%) | 127 (21.7%) | 645 (36.4%) |
Male | 471 (39.6%) | 372 (63.6%) | 843 (47.5%) |
Missing information | 200 (16.7%) | 86 (14.7%) | 286 (16.1%) |
Status | |||
Alive | 380 (32.0%) | 288 (49.2%) | 668 (37.7%) |
Dead | 451 (37.9%) | 297 (50.8%) | 748 (42.2%) |
Missing information | 358 (30.1%) | 0 (0%) | 358 (20.2%) |
Age (years) | |||
Mean (sd) | 64.6 (9.97) | 67.2 (8.49) | 65.7 (9.44) |
Median [min, max] | 65.0 [33.0, 88.0] | 68.0 [39.0, 90.0] | 67.0 [33.0, 90.0] |
Missing information | 511 (43.0%) | 91 (15.6%) | 602 (33.9%) |
Stage | |||
I | 4 (0.3%) | 3 (0.5%) | 7 0.4%) |
IA | 227 (19.1%) | 133 (22.7%) | 360 (20.3%) |
IB | 183 (15.4%) | 179 (30.6%) | 362 (20.4%) |
II | 1 (0.1%) | 3 (0.5%) | 4 (0.2%) |
IIA | 81 (6.8%) | 80 (13.7%) | 161 (9.1%) |
IIB | 102 (8.6%) | 95 (16.2%) | 197 (11.1%) |
III | 25 (2.1%) | 1 (0.2%) | 26 (1.5%) |
IIIA | 111 (9.3%) | 59 (10.1%) | 170 (9.6%) |
IIIB | 45 (3.8%) | 18 (3.1%) | 63 (3.6%) |
IV | 321 (27.0%) | 6 (1.0%) | 327 (18.4%) |
IVA | 16 (1.3%) | 1 (0.2%) | 17 (1.0%) |
Missing information | 73 (6.1%) | 7 (1.2%) | 80 (4.5%) |
Stage (grouped) | |||
Early-stage (I/IA/IB/II/IIA/IIB) | 598 (50.3%) | 493 (84.3%) | 1091 (61.5%) |
Late-stage (III/IIIA/IIIB/IV/IVA) | 518 (43.6%) | 85 (14.5%) | 603 (34.0%) |
Missing information | 73 (6.1%) | 7 (1.2%) | 80 (4.5%) |
Therapy | |||
Chemotherapy | 964 (78%) | 585 (100%) | 1549(85%) |
Immunotherapy | 225 (18%) | 0 (0%) | 225 (12%) |
Radchemotherapy | 14 (1%) | 0 (0%) | 14 (1%) |
Radiotherapy | 10 (1%) | 0 (0%) | 10 (1%) |
Other | 24 (2%) | 0 (0%) | 0 (0%) |
